Mylan pays $30M to settle charges of misleading investors on EpiPen rebates

Mylan pays $30M to settle charges of misleading investors on EpiPen rebates

STAT Plus: Mylan pays $30 million to settle charges of misleading investors over probe into EpiPen Medicaid rebates

By ED SILVERMAN

STAT

The SEC contended Mylan did not disclose or accrue for losses relating to a Justice Department probe before it was settled in October 2016.

READ MORE